Expression and prognostic value of SULT1A2 in bladder cancer

Chao,Yinghui; Ou,Qifeng; Shang,Jin

doi:10.3892/etm.2021.10211

Expression and prognostic value of SULT1A2 in bladder cancer

Authors:
- Yinghui Chao
- Qifeng Ou
- Jin Shang
View Affiliations

Affiliations: Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Laboratory of Surgery, The First Affiliated Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: May 19, 2021 https://doi.org/10.3892/etm.2021.10211
Article Number: 779
Copyright: © Chao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sulfotransferase Family 1A Member 2 (SULT1A2) is a protein coding gene. Several studies have reported that SULT1A2 may have a chemical carcinogenic effect if expressed as a functional protein. The present study aimed to investigate the expression and potential role of SULT1A2 in bladder cancer (BC). Data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases were used to analyze SULT1A2 expression in BC. In addition, reverse transcription‑quantitative PCR and western blot analyses were performed to detect SULT1A2 expression in BC cells and tissues. Immunohistochemistry analysis was performed on 100 formalin‑fixed, paraffin‑embedded BC tissues and corresponding adjacent normal bladder tissues (ANBTs) to verify SULT1A2 expression and determine the clinical significance of SULT1A2 in BC. Gene set enrichment analysis (GSEA) was performed to determine the potential biological processes and internal molecular mechanisms. The results demonstrated that SULT1A2 was highly expressed in BC tissues compared with ANBTs. Furthermore, high SULT1A2 expression was significantly associated with the staging of BC. Analyses of TCGA datasets and BC tissue microarray indicated that high SULT1A2 expression was significantly associated with a favorable overall survival in patients with BC. In addition, GSEA revealed pathways, diseases and biological processes associated with SULT1A2. Taken together, the results of the present study suggest that SULT1A2 acts as an oncogene in BC, and thus may serve as a biomarker for tumor staging and prognosis in patients with BC.

View Figures

View References

1	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 507:315–322. 2014.PubMed/NCBI View Article : Google Scholar
2	Figueroa JD, Malats N, García-Closas M, Real FX, Silverman D, Kogevinas M, Chanoc S, Welch R, Dosemeci M, Lan Q, et al: Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis. 29:1955–1962. 2008.PubMed/NCBI View Article : Google Scholar
3	Schulster M: Bladder cancer academy 2019 selected summaries. Rev Urol. 21:23–28. 2019.PubMed/NCBI
4	Vlachostergios PJ and Faltas BM: The molecular limitations of biomarker research in bladder cancer. World J Urol. 37:837–848. 2019.PubMed/NCBI View Article : Google Scholar
5	Dong D, Ako R and Wu B: Crystal structures of human sulfotransferases: Insights into the mechanisms of action and substrate selectivity. Expert Opin Drug Metab Toxicol. 8:635–646. 2012.PubMed/NCBI View Article : Google Scholar
6	Kauffman FC: Conjugation-deconjugation reactions in drug metabolism and toxicity. Fed Proc. 46:2434–2445. 1987.PubMed/NCBI
7	Cole P, Monson RR, Haning H and Friedell GH: Smoking and cancer of the lower urinary tract. N Engl J Med. 284:129–134. 1971.PubMed/NCBI View Article : Google Scholar
8	Cole P, Hoover R and Friedell GH: Occupation and cancer of the lower urinary tract. Cancer. 29:1250–1260. 1972.PubMed/NCBI View Article : Google Scholar
9	Sabbioni G, Jones CR, Sepai O, Hirvonen A, Norppa H, Järventaus H, Glatt H, Pomplun D, Yan H, Brooks LR, et al: Biomarkers of exposure, effect, and susceptibility in workers exposed to nitrotoluenes. Cancer Epidemiol Biomarkers Prev. 15:559–566. 2006.PubMed/NCBI View Article : Google Scholar
10	Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, Martinek V, Sopko B, Wolf CR, Schmeiser HH and Phillips DH: Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res. 65:2644–2652. 2005.PubMed/NCBI View Article : Google Scholar
11	Sidorenko VS, Attaluri S, Zaitseva I, Iden CR, Dickman KG, Johnson F and Grollman AP: Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis. 35:1814–1822. 2014.PubMed/NCBI View Article : Google Scholar
12	Nowell S, Green B, Tang YM, Wiese R and Kadlubar FF: Examination of human tissue cytosols for expression of sulfotransferase isoform 1A2 (SULT1A2) using a SULT1A2-specific antibody. Mol Pharmacol. 67:394–399. 2005.PubMed/NCBI View Article : Google Scholar
13	Svendsen C, Meinl W, Glatt H, Alexander J, Knutsen HK, Hjertholm H, Rasmussen T and Husøy T: Intestinal carcinogenesis of two food processing contaminants, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 5-hydroxymethylfurfural, in transgenic FVB min mice expressing human sulfotransferases. Mol Carcinog. 51:984–992. 2012.PubMed/NCBI View Article : Google Scholar
14	Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME and Lotan Y: Bladder cancer. Nat Rev Dis Primers. 3(17022)2017.PubMed/NCBI View Article : Google Scholar
15	Situ DR, Hu Y, Zhu ZH, Wang J, Long H and Rong TH: Prognostic relevance of β-catenin expression in T2-3N0M0 esophageal squamous cell carcinoma. World J Gastroenterol. 16:5195–5202. 2010.PubMed/NCBI View Article : Google Scholar
16	Regier N and Frey B: Experimental comparison of relative RT-qPCR quantification approaches for gene expression studies in poplar. BMC Mol Biol. 11(57)2010.PubMed/NCBI View Article : Google Scholar
17	Song Y, Jin D, Ou N, Luo Z, Chen G, Chen J, Yang Y and Liu X: Gene expression profiles identified novel urine biomarkers for diagnosis and prognosis of high-grade bladder urothelial carcinoma. Front Oncol. 10(394)2020.PubMed/NCBI View Article : Google Scholar
18	Huang YD, Shan W, Zeng L and Wu Y: Screening of differentially expressed genes related to bladder cancer and functional analysis with DNA microarray. Asian Pac J Cancer Prev. 14:4553–4557. 2013.PubMed/NCBI View Article : Google Scholar
19	Heidegger I, Borena W and Pichler R: The role of human papilloma virus in urological malignancies. Anticancer Res. 35:2513–2519. 2015.PubMed/NCBI
20	Kachrilas S, Dellis A, Papatsoris A, Avgeris S, Anastasiou D, Gavriil A, Horti M, Tseleni Balafouta S, Livadas K, Stravopodis DJ, et al: PI3K/AKT pathway genetic alterations and dysregulation of expression in bladder cancer. J BUON. 24:329–337. 2019.PubMed/NCBI
21	Liu J, Li H, Shen S, Sun L, Yuan Y and Xing C: Alternative splicing events implicated in carcinogenesis and prognosis of colorectal cancer. J Cancer. 9:1754–1764. 2018.PubMed/NCBI View Article : Google Scholar
22	Peng CT, Chen JC, Yeh KT, Wang YF, Hou MF, Lee TP, Shih MC, Chang JY and Chang JG: The relationship among the polymorphisms of SULT1A1, 1A2 and different types of cancers in Taiwanese. Int J Mol Med. 11:85–89. 2003.PubMed/NCBI
23	McGowan PM, Kirstein JM and Chambers AF: Micrometastatic disease and metastatic outgrowth: Clinical issues and experimental approaches. Future Oncol. 5:1083–1098. 2009.PubMed/NCBI View Article : Google Scholar
24	Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, Ali R and Sarkar FH: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat. 122:337–346. 2010.PubMed/NCBI View Article : Google Scholar
25	Liguori M, Solinas G, Germano G, Mantovani A and Allavena P: Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. Cancers (Basel). 3:3740–3761. 2011.PubMed/NCBI View Article : Google Scholar
26	Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M and Adam L: Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 65:10524–10535. 2005.PubMed/NCBI View Article : Google Scholar
27	Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, Wilson S and Koul HK: p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res. 70:832–841. 2010.PubMed/NCBI View Article : Google Scholar
28	Zhao L, Zhang T, Geng H, Liu ZQ, Liang ZF, Zhang ZQ, Min J, Yu DX and Zhong CY: MAPK/AP-1 pathway regulates benzidine-induced cell proliferation through the control of cell cycle in human normal bladder epithelial cells. Oncol Lett. 16:4628–4634. 2018.PubMed/NCBI View Article : Google Scholar
29	Sun X, Zhang T, Deng Q, Zhou Q, Sun X, Li E, Yu D and Zhong C: Benzidine induces epithelial-mesenchymal transition of human bladder cancer cells through activation of ERK5 pathway. Mol Cells. 41:188–197. 2018.PubMed/NCBI View Article : Google Scholar
30	Houédé N and Pourquier P: Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use in the treatment of bladder cancers. Pharmacol Ther. 145:1–18. 2015.PubMed/NCBI View Article : Google Scholar
31	Khadjavi A, Mannu F, Destefanis P, Sacerdote C, Battaglia A, Allasia M, Fontana D, Frea B, Polidoro S, Fiorito G, et al: Early diagnosis of bladder cancer through the detection of urinary tyrosine-phosphorylated proteins. Br J Cancer. 113:469–475. 2015.PubMed/NCBI View Article : Google Scholar
32	Douglawi A and Masterson TA: Updates on the epidemiology and risk factors for penile cancer. Transl Androl Urol. 6:785–790. 2017.PubMed/NCBI View Article : Google Scholar
33	Berrada N, Al-Bouzidi A, Ameur A, Abbar M, El-Mzibri M, Ameziane-El-Hassani R, Benbacer L, Khyatti M, Qmichou Z, Amzazi S and Attaleb M: Human papillomavirus detection in Moroccan patients with bladder cancer. J Infect Dev Ctries. 7:586–592. 2013.PubMed/NCBI View Article : Google Scholar
34	Alexander RE, Hu Y, Kum JB, Montironi R, Lopez-Beltran A, Maclennan GT, Idrees MT, Emerson RE, Ulbright TM, Grignon DG, et al: p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Mod Pathol. 25:1526–1533. 2012.PubMed/NCBI View Article : Google Scholar
35	Polesel J, Gheit T, Talamini T, Shahzad N, Lenardon O, Sylla B, La Vecchia C, Serraino D, Tommasino M and Franceschi S: Urinary human polyomavirus and papillomavirus infection and bladder cancer risk. Br J Cancer. 106:222–226. 2012.PubMed/NCBI View Article : Google Scholar
36	Weinstein SJ, Ziegler RG, Selhub J, Fears TR, Strickler HD, Brinton LA, Hamman RF, Levine RS, Mallin K and Stolley PD: Elevated serum homocysteine levels and increased risk of invasive cervical cancer in US women. Cancer Causes Control. 12:317–324. 2001.PubMed/NCBI View Article : Google Scholar
37	Moonen PM, Bakkers JM, Kiemeney LA, Schalken JA, Melchers WJ and Witjes JA: Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol. 52:464–468. 2007.PubMed/NCBI View Article : Google Scholar